Full Text View
Tabular View
No Study Results Posted
Related Studies
Evaluation of L-Alpha-Acetylmethadol (LAAM) in Methadone Patients - 5
This study has been completed.
Study NCT00000356   Information provided by National Institute on Drug Abuse (NIDA)
First Received: September 20, 1999   Last Updated: June 23, 2005   History of Changes

September 20, 1999
June 23, 2005
June 1991
 
 
 
Complete list of historical versions of study NCT00000356 on ClinicalTrials.gov Archive Site
 
 
 
Evaluation of L-Alpha-Acetylmethadol (LAAM) in Methadone Patients - 5
Pharmacokinetics of LAAM in Methadone Patients

The purpose of this study is to determine the pharmacokinetics of L-alpha-acetylmethadol (LAAM) in adults transferred from methadone maintenance treatment for opiate dependence.

 
Phase II
Interventional
Treatment
  • Opioid-Related Disorders
  • Substance-Related Disorders
Drug: LAAM
 
 

*   Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
 
Completed
0
 
 

Please contact site for information.

Both
 
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00000356
 
NIDA-3-0012-5, Y01-3-0012-5
National Institute on Drug Abuse (NIDA)
University of Pennsylvania
Principal Investigator: Charles O'Brien, M.D., Ph.D. PDVAMC Treatment Research Center
National Institute on Drug Abuse (NIDA)
February 1992

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP